Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Stoke Therapeutics Inc shares valued at $128,411 were sold by Allan Jonathan on Dec 08 ’25. At $32.28 per share, Allan Jonathan sold 3,978 shares. The insider’s holdings dropped to 11,831 shares worth approximately $0.39 million following the completion of this transaction.
Also, Kaye Edward M. MD sold 13,430 shares, netting a total of over 433,385 in proceeds. Following the sale of shares at $32.27 each, the insider now holds 49,124 shares.
Before that, EDWARD M KAYE had added 13,430 shares to its account. In a trade valued at $414,584, the Director bought Stoke Therapeutics Inc shares for $30.87 each.
As published in their initiating research note from Jefferies on July 18, 2025, Stoke Therapeutics Inc [STOK] has been a Buy and the price target has been revised to $30. Analysts at Chardan Capital Markets started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. Earlier on March 26, 2024, TD Cowen upgraded its rating. Their new recommendation was “an Outperform” for STOK stock which previously was a “a Market perform”.
Analyzing STOK Stock Performance
On last trading session, Stoke Therapeutics Inc [NASDAQ: STOK] plunged -2.23% to $32.86. The stock’s lowest price that day was $32.43, but it reached a high of $34.05 in the same session. During the last five days, there has been a drop of approximately -3.78%. Over the course of the year, Stoke Therapeutics Inc shares have jumped approximately 172.47%. Shares of the company reached a 52-week high of $38.69 on 10/16/25 and a 52-week low of $5.35 on 04/09/25.
Support And Resistance Levels for Stoke Therapeutics Inc (STOK)
According to the 24-hour chart, there is a support level at 32.18, which, if violated, would cause prices to drop to 31.49. In the upper region, resistance lies at 33.80. The next price resistance is at 34.73. RSI (Relative Strength Index) is 57.70 on the 14-day chart, showing neutral technical sentiment.
Is Stoke Therapeutics Inc subject to short interest?
Stocks of Stoke Therapeutics Inc saw a sharp steep in short interest on 2025-11-28 dropping by -0.11 million shares to 10.56 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 10.67 million shares. A decline of -1.02% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.39 of the overall float, the days-to-cover ratio (short ratio) decline to 9.39.
Which companies own the most shares of Stoke Therapeutics Inc (STOK)?
In terms of Stoke Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 35 in the next 12 months, up nearly 4.14% from the previous closing price of $33.61. Analysts anticipate Stoke Therapeutics Inc stock to reach 50 by 2025, with the lowest price target being 28. In spite of this, 5 analysts ranked Stoke Therapeutics Inc stock as Buy at the end of 2025.
